Programa de Pós-Graduação em Biotecnologia-PPGBIOTEC, Universidade Tecnológica Federal do Paraná, Dois Vizinhos, Paraná, Brazil.
Laboratório Multiusuário de Análises Biológicas e Biologia Molecular (BioMol)-UTFPR, Grupo de Pesquisa em Biologia Molecular-UTFPR, Dois Vizinhos, Paraná, Brazil.
J Med Virol. 2023 Jun;95(6):e28882. doi: 10.1002/jmv.28882.
Several vaccines have been produced in 2 years of the COVID-19 pandemic to control the infection outbreak. This study demonstrated the success of vaccination in controlling COVID-19 cases and deaths in a small city (41 424 people) with a low population density in Brazil. This study was based on a 1-year dataset since the application of the first dose in January 2021. The results show a reduction in positive cases and deaths as the vaccination coverage increased in the city, mainly after 15 000 inhabitants were vaccinated (35.21% of the population) in July 2021. At the time, 49.06% of administered vaccines were ChAdOx1-S recombinant, 39.80% inactivated SARS-CoV-2 virus (CZ02 strain), 9.70% Tozinameran, and 1.44% Ad26.COV2-S recombinant. From August 2021, a marked reduction in daily positive cases and deaths was observed, and incidence (≤2.49 per 1000 inhabitants) and mortality (≤0.02 per 1000 inhabitants) rates remained stabilized until January 2022, when a new outbreak occurred upon the emergence of the Omicron variant. However, the mortality rate (0.07 per 1000 inhabitants) remained low regardless of the Omicron high incidence rate (68.41 per 1000 inhabitants). These data demonstrate the COVID-19 vaccination effectiveness with a threshold of 35.21% of the population vaccinated in this city model.
在 COVID-19 大流行的 2 年内,已经生产了几种疫苗来控制感染爆发。本研究展示了在巴西一个人口密度低的小城市(41424 人)中,接种疫苗在控制 COVID-19 病例和死亡方面的成功。本研究基于自 2021 年 1 月首次接种疫苗以来的 1 年数据集。结果表明,随着城市接种覆盖率的增加,阳性病例和死亡人数减少,主要是在 2021 年 7 月接种了 15000 名居民(占人口的 35.21%)之后。当时,接种的疫苗中 49.06%为 ChAdOx1-S 重组疫苗,39.80%为灭活 SARS-CoV-2 病毒(CZ02 株),9.70%为 Tozinameran,1.44%为 Ad26.COV2-S 重组疫苗。自 2021 年 8 月以来,每日阳性病例和死亡人数明显减少,发病率(≤2.49/1000 居民)和死亡率(≤0.02/1000 居民)保持稳定,直到 2022 年 1 月,当奥密克戎变体出现时发生了新的疫情。然而,死亡率(0.07/1000 居民)保持在低水平,无论奥密克戎的高发病率(68.41/1000 居民)如何。这些数据证明了 COVID-19 疫苗在该市模型中接种率达到 35.21%的有效性。